Results 51 to 60 of about 27,333,880 (308)

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, EarlyView.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; ClinicalTrials.gov identifier ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) Network investigators   +14 more
wiley   +1 more source

Treatment results of patients with multiple and extensive drug resistance registered in 2012 in the Russian Federation and in the world

Туберкулез и болезни лёгких, 2016
The chemotherapy results have been analyzed in tuberculosis patients suffering from multiple drug resistance registered for treatment in the Russian Federation in 2011-2012 compared with the treatment outcomes of MDR patients registered for treatment in ...
S. A. Sterlikov, V. V. Testov, I. A. Vasilieva   +2 more
doaj  

Characterization of Mycobacterium orygis as M. tuberculosis Complex Subspecies

Emerging Infectious Diseases, 2012
The oryx bacilli are Mycobacterium tuberculosis complex organisms for which phylogenetic position and host range are unsettled. We characterized 22 isolates by molecular methods and propose elevation to subspecies status as M. orygis. M.
J. van Ingen, Z. Rahim, A. Mulder, M. Boeree, Roxane Siméone, R. Brosch, D. van Soolingen   +6 more
semanticscholar   +1 more source

Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis.

New England Journal of Medicine, 2019
BACKGROUND Results of an earlier analysis of a trial of the M72/AS01E candidate vaccine against Mycobacterium tuberculosis showed that in infected adults, the vaccine provided 54.0% protection against active pulmonary tuberculosis disease, without ...
D. Tait, M. Hatherill, Olivier Van Der Meeren, A. Ginsberg, Elana van Brakel, B. Salaun, T. Scriba, E. J. Akité, H. Ayles, A. Bollaerts, M. Demoitié, A. Diacon, T. Evans, P. Gillard, Elizabeth Hellström, J. Innes, Maria Lempicki, M. Malahleha, N. Martinson, Doris Mesia Vela, M. Muyoyeta, V. Nduba, Thierry G Pascal, M. Tameris, Friedrich Thienemann, R. Wilkinson, F. Roman   +26 more
semanticscholar   +1 more source

Redefining Therapies for Drug‐Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design

Advanced Healthcare Materials, EarlyView.
Antimicrobial peptide (AMP)‐loaded nanocarriers provide a multifunctional strategy to combat drug‐resistant Mycobacterium tuberculosis. By enhancing intracellular delivery, bypassing efflux pumps, and disrupting bacterial membranes, this platform restores phagolysosome fusion and macrophage function.
Christian S. Carnero Canales, Jessica Ingrid Marquez Cazorla, Renzo Marianito Marquez Cazorla, Aline Martins dos Santos, Jonatas Lobato Duarte, Letícia Oliveira Catarin Nunes, Túlio Custódio Reis, Lara Cerazi Salvador, Norival Alves Santos‐Filho, Rafael Miguel Sábio, Hélder A. Santos, Fernando Rogério Pavan   +11 more
wiley   +1 more source

The impact of the coexistence of mycobacterium avium with mycobacterium tuberculosis on the result of GeneXpert and MGIT susceptibility test

Journal of Infection and Public Health, 2020
Rapid tests to diagnose tuberculosis relies on molecular detection of the M. tuberculosis. GeneXpert MTB/RIF test identifies M. tuberculosis and rifampicin resistance. We present a case of simultaneous coinfection with M. tuberculosis and M. avium.
Ali M. Bazzi, Yem Abulhamayel, Ali A. Rabaan, Jaffar A. Al-Tawfiq   +3 more
doaj   +1 more source

Dual‐Peptide Nanoplatform: Mesoporous Silica Nanoparticles Functionalized With a Cell‐Penetrating Peptide and Loaded With Rationally Designed Antimicrobial Peptides for Tuberculosis Therapy

Advanced Healthcare Materials, EarlyView.
Machine learning–guided engineering of a plectasin‐derived peptide yields DC05, a potent antimycobacterial candidate. Encapsulation into tuftsin‐functionalized mesoporous silica nanoparticles enhances intracellular delivery, stability, and activity against Mycobacterium tuberculosis while maintaining low cytotoxicity and minimal hemolysis. The combined
Christian S. Carnero Canales, Cesar Augusto Roque‐Borda, Ana Carolina Cerqueira Negri, Oswaldo Ramirez Delgado, Letícia Oliveira Catarin Nunes, Flávia Aparecida Resende, Hernane Barud, Norival Alves Santos‐Filho, Saulo Santesso Garrido, Karen Cristina Oliveira, Alexandra Ivo de Medeiros, Rafael Miguel Sábio, Fernando Rogério Pavan   +12 more
wiley   +1 more source

Isoniazid-resistant TB and associated factors in Ethiopia

Public Health Action
BACKGROUND: Isoniazid-resistant, rifampicin-susceptible Mycobacterium tuberculosis (Hr-TB) is the most common form of drug-resistant TB (DR-TB). We investigated the prevalence of and risk factors for Hr-TB in Ethiopia.
S. Moga, T. Abebe, K. Bobosha, A. Alemu, G. Diriba, K.R.V. Harrington, R.H. Lyles, H.M. Blumberg, R.R. Kempker   +8 more
doaj   +1 more source

Engineered ETS1‐Nanoconjugate Restores Immune Homeostasis through Dual Immune‐Vascular Modulation in Relapsing and Progressive Multiple Sclerosis

Advanced Healthcare Materials, EarlyView.
The biomimetic nanoplatform IMNP (ETS1 pDNA/PBAE@ITP‐MM) undergoes targeted disassembly at inflammatory vascular sites to release the ETS1 plasmid (pETS1). This release initiates a cascade of effects that inhibit pathogenic pathways and support immune homeostasis. (Abbreviations: EndMT, endothelial‐to‐mesenchymal transition; EC, endothelial cell; TC, T
Feng Zhang, Si‐Bo Yang, Yan Luo, Xiao‐Di Sun, Bo‐Hao Chang, Da‐Qiang Zhou, Jun‐Jie Jiang, Ya‐Nan Li, Jie‐Hong Wu, Hui‐Juan Jin, Hang Yang, Hang Hu, Yi‐Fan Zhou, Bo Hu   +13 more
wiley   +1 more source

Host Immune Responses Differ between M. africanum- and M. tuberculosis-Infected Patients following Standard Anti-tuberculosis Treatment [PDF]

PLOS Neglected Tropical Diseases, 2016
Epidemiological differences exist between Mycobacterium africanum (Maf)- and Mycobacterium tuberculosis (Mtb)-infected patients, but to date, contributing host factors have not been characterised. We analysed clinical outcomes, as well as soluble markers and gene expression profiles in unstimulated, and ESAT6/CFP-10-, whole-Maf- and Mtb-stimulated ...
Tientcheu, L.D., Haks, M.C., Agbla, S.C., Sutherland, J.S., Adetifa, I.M., Donkor, S., Quinten, E., Daramy, M., Antonio, M., Kampmann, B., Ottenhoff, T.H.M., Dockrell, H.M., Ota, M.O.   +12 more
openaire   +5 more sources